Hjem › Metastatisk kreft › Oklahoma
Kliniske studier for Metastatisk kreft i Oklahoma
16 studier for Metastatisk kreft søker deltakere på steder i Oklahoma.
Byer i Oklahoma
Offisiell studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT05803382Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213804Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT06311214FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Oklahoma - Health Sciences Center, Oklahoma City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT05614739Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT05687110Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 31. jul. 2026 · NCT05691491A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT04657068Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 19. mai 2026 · NCT05431270Collection and Storage of Tissue and Blood Samples From Patients With Cancer
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererObservasjonsstudie
2 Months · Alle kjønn · Oppdatert 5. mar. 2026 · NCT02474160Circulating Tumor DNA Response In Urothelial Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. feb. 2026 · NCT07183319SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Spine Radiosurgery for Symptomatic Metastatic Neoplasms
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. okt. 2025 · NCT05617716A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT05107674Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.